report result provid updat
syro loss per share higher estim loss
oper expens million higher estim
million remark varianc quarter adjust
outlook time potenti approv launch base today
updat make adjust account recent financ
better clariti time data ow estim result
move expect potenti fda file approv launch
quarter believ clariti around data time reduc risk associ
syro posit impact risk-adjust revenu estim
align chang expect potenti launch
lower estim revenu oper incom estim
revenu reduc million prior
million adjust time launch sale ramp revenu estim
million
chang estim revenu along correspond chang
estim expens ramp result oper loss increas
million million chang slightli posit loss
million reduc
combin impact financ anticip financ
need result loss per share increas
loss increas prior reduc
ep estim ep
syro announc plan open expans cohort on-going
phase trial evalu singl agent combin
carboplatin multipl ovarian cancer patient popul plan add
expans cohort hr-posit metastat breast cancer current
revenu estim anticip upsid post
syro expect cash recent million capit rais fund
oper
therapi cancer diseas
master
switch diseas gene open
novel
analyst certif import disclosur see disclosur appendix
current estim syro could launch result
revenu million grow million
turn result posit net earn
estim syro suffici cash fund develop
program estim syro
need rais total million fund develop
platform develop
higher sell price syro product model
gain fda approv indic model
faster market penetr estim
syro pharmaceut high-qual earli stage
compani impress scientif found view
base expect lead product
estim syro could revenu grow
revenu million arriv target price
syro stock acknowledg possibl signific
downsid estim due inher risk drug
develop worst case syro stock could
littl valu use risk/reward trade-off rate syro
data phase singl agent studi
data phase ii combo studi azacitidin
guidanc fda-fil strategi
ii combo studi
phase
fail gain fda approv
unfavor price slow physician adopt
loss patent protect
structur chang healthcar market
use biotech group price-to-sal multipl risk-adjust revenu million discount earli stage
biotechnolog return expect per year arriv price target per share
believ syro success next five year highli depend fda approv launch current experiment compound
gain approv risk includ secur favor price third parti reimburs patient drug cost
patient behavior physician adopt product maintain patent protect structur chang healthcar market
outperform price target estim syro could launch
first drug acut myeloid leukemia myeloid dysplast syndrom earli
compani syro stage develop pre-commerci
primarili focu potenti futur revenu valu base expect syro
launch first product next year estim syro product
revenu grow million howev case
development-stag compani estim carri degre risk
basi estim revenu million appli industri
revenu multipl discount estim revenu risk-of-failur arriv
target price
howev acknowledg possibl signific downsid estim due
inherit risk drug develop worst case stock could
littl valu
valuat methodolog compani depend develop stage
product meaning percentag estim futur earn base appli
industri price-to-earnings price-to-earnings multipl price-to-earnings growth rate ratio price-to-sal
multipl estim futur earn revenu discount valu base
estim risk failur use biotechnolog group multipl deriv
averag multipl compani profit sever year exhibit
defin biotechnolog industri equal weight stock biotechnolog
compani posit earn
exhibit price earn ratio price-to-earnings price-to-earnings growth ratio price-to-sal
calcul base price group last day month earn per share
estim wall street analyst forward year sourc data use
calcul databas compil maintain oppenheim co use estim
factset price quot servic
typic appli averag multipl futur estim revenu earn
determin discount base compani stage develop use risk
failur base phase develop publish tuft center studi
drug develop base data failur rate potenti drug phase
develop approxim progress phase ii develop
failur rate approxim progress phase develop
failur rate approxim actual file approv
food drug administr fda failur rate
pipelin two experiment therapi howev
model current account one compound revenu impact
first anticip commerci impact
estim gener revenu start account
model revenu anticip file fda earli
therefor use discount histor failur rate phase ii pivot
stage drug develop revenu estim million result
risk-adjust revenu estim million
conclus use biotech group price-to-sal risk-adjust
revenu million discount earli stage biotechnolog invest return
arriv price target per share
believ greatest risk syro stock next two year file approv
launch experiment product launch delay result
estim revenu reduc million appli industri
sale multipl expect invest return stock could valu per
share fail demonstr clinic benefit on-going
studi experi syross stock could valu even lower level
analysi
syro loss per share higher estim loss
oper expens million higher estim million
remark varianc quarter detail analysi
provid exhibit
exhibit analysi compar prior period opco estim
inc nasdaq-syr incom analysi million except per share data estimatedactualchang bp actualq chang bp actuali chang bp priorrevisedchang product revenu relat good incom incom share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request
syro expect cash recent million capit rais fund oper
estim oper loss reduc nearli account
increas collabor revenu includ million up-front payment
addit increas estim share outstand
account equiti offer close earli februari incyt
invest also decreas interest expens longer estim need
debt financ oper combin result reduc
estim loss per share prior loss
better clariti time data estim
result move expect potenti fda file approv
launch quarter lead us lower estim revenu oper
incom estim revenu reduc
million prior million adjust time launch sale ramp
revenu estim million
chang estim revenu along correspond chang estim
expens ramp result oper loss increas million
million chang slightli posit loss million
reduc combin impact financ
anticip financ need result estim loss per share
increas estim loss per share increas
prior reduc ep
estim ep
detail analysi chang outlook provid exhibit
exhibit analysi chang estim sinc last report
inc nasdaq-syr incom analysi million except per share data priorrevisedchang bp priorrevisedchang bp priorrevisedchang bp priorrevisedchang product revenu relat good incom incom share share per per share dilut compani data oppenheim co estimatesaddit inform avail upon request
syro announc websit
syro plan open expans cohort on-going phase
trial evalu singl agent combin
carboplatin multipl ovarian cancer patient popul compani also
plan add expans cohort evalu combin
fulvestr hr-posit metastat breast cancer patient progress
treatment inhibitor plu aromatas inhibitor
januari syro announc clinic suppli agreement janssen
research develop term agreement janssen
suppli daratumumab combin dose cohort biomarker-
posit relaps refractori aml higher-risk md patient syro
on-going phase ii trial
syro pharmaceuticalsproductindicationpartner/ mdsbreast tumor tnbc ovarian sclcblood cancer aml allor inhibitorcancerclin trialspre-clinicaliiiiii outperform
syro announc websit
syro plan report clinic data fourth quarter
dose-escal portion on-going phase trial advanc
compani plan report clinic data fourth quarter
cohort on-going phase ii trial evalu combin
azacitidin rara biomarker-posit newli diagnos acut
myeloid leukemia aml patient suitabl candid
syro plan report clinic data fourth quarter pilot
cohort on-going phase ii trial evalu combin
daratumumab rara biomarker-posit relaps refractori
aml higher-risk myelodysplast syndrom md patient
joseph ferra appoint chief
syro announc march appoint joseph ferra chief
financi offic mr ferra recent serv manag director co-
head healthcar invest bank jmp secur prior jmp
member invest bank group ub jp morgan earlier
career mr ferra serv sale engin role life scienc tool
industri earn mba stephen ross school busi
univers michigan obtain chemistri distinct
believ mr ferra bring extens corpor financ expertis syro
product candidatestudyindicationexpect time iisolid daratumumabphas iiaml azacitidinephas iiaml syro pharmaceut
syro announc websit
provid summari financi outlook full financi
model product detail avail upon request
name salari bonusopt award share own experi summary/ career highlightsn simonian presid chief execut offic serv ceo sinc juli dr simonian recent chief medic offic senior vice presid clinic medic regulatori affair dr simonian inc serv vice presid clinic develop dr simonian director inc biotechnolog industri organ david roth chief medic serv sinc decemb dr roth employ infin pharmaceut inc septemb septemb serv recent execut vice presid chief medic offic previous senior vice presid clinic develop medic affair prior join infin dr roth vice presid earli develop oncolog busi unit inc dr roth board certifi hematologist eric olson ph chief scientif officernaha serv cso sinc april previous serv research vice presid respiratori diseas incorpor may dr olson also held posit director antibacteri molecular scienc depart warner-lambert well research scientist upjohn compani acquir inc hold ph microbiolog immunolog jorg cond chief strategi officernaha serv chief strategi offic sinc april previous serv cfo chief product offic may may prior syro mr cond previous serv variou role knome inc genom compani includ found chief execut offic chief financi offic chief product offic comment syro talent experienc manag team outperform
inc nasdaq-syr leah rush cannestim sale earningsoppenheim co million except per share statement product revenu relat growth incom incom share share per per share dilut sheet stockhold statementoper cash flow per cash flow per compani data oppenheim co estimatesaddit inform avail upon request
stock price compani mention report
